Skip to main content
. 2021 Feb 18;11(2):39. doi: 10.1038/s41408-021-00429-z

Fig. 5. Combination of ibrutinib and venetoclax effectively eliminates both resting and dividing CLL subpopulations in ibrutinib-resistant cases.

Fig. 5

Live cell numbers and CFSE profiles of four ibrutinib-resistant cases are shown. Experimental conditions were identical to Fig. 4.